Covenant doubles down on Hill Research after 4x revenue jump
What's the deal? Covenant Venture CapitalDealroom has a profile for this one. Try Dealroom → has made a follow-on investment in Hill ResearchDealroom has a profile for this one. Try Dealroom →, a Princeton-based startup building AI-powered infrastructure for clinical trial biostatistics and regulatory workflows.
The New Jersey Economic Development Authority (NJEDA) Evergreen Innovation Fund participated as a limited partner in the round, announced July 1, 2026.
Hill Research's platform, TriClick, automates the statistical programming and regulatory submission pipeline, from a locked clinical database to an FDA filing.
The company says TriClick delivers submission-ready outputs up to 300 times faster, with fewer errors and full traceability.
Why now? Covenant cited hard numbers. Hill Research grew revenue roughly fourfold from 2024 to 2025, and its enterprise value doubled over the same period.
Heading into 2026, the company targets a further 5-8x revenue growth, driven by rising adoption across pharmaceutical, biotech, and clinical research organisations.
"Hill Research exemplifies the kind of Deep Tech innovation we champion — an AI-first engine that automates regulated clinical trial data and statistics workflows while producing submission-grade outputs," said René Bastón, venture partner at Covenant.
Founder and chief executive officer Louise Liu said the new capital will help expand Hill's AI-enabled offerings "while maintaining the scientific rigor our sponsors count on."
What could go wrong? Regulatory workflows demand precision and traceability, where errors carry real cost. Any slip in compliance could undercut trust with pharma clients and regulators.
Hill's ambitious 2026 targets also assume adoption keeps accelerating — a steep bar for any scaleup to clear.
The signal: Covenant's follow-on into an early-stage company underscores growing investor conviction in generative AI applied to regulated, high-stakes fields like clinical trials rather than consumer tools. Backed by NJEDA's government-linked Evergreen Innovation Fund, the deal also reflects New Jersey's push to anchor life sciences and deep tech founders in the state through public-private capital.
